Eagle Bags Vasopressin Exclusivity And Details Launch Plans
US Agency Also Dishes Out Tentative Nod For Amphastar’s’ ANDA Product
Executive Summary
Generic competition to Vasostrict is nearing in the US after the FDA confirmed Eagle’s previously unresolved potential for 180-day market exclusivity.
You may also be interested in...
Multiple Vasostrict ANDAs Rival Eagle In Competitive Market
Amphastar, Amneal and Aurobindo are among ANDA sponsors confirming USFDA approval for generic versions of Endo’s Vasostrict (vasopressin) 20 units/ml single-dose vial – as first mover Eagle Pharmaceuticals remains locked in patent-litigation proceedings with the originator.
Primatene Mist Drives Amphastar Sales Growth
Amphastar reported double-digit growth in the fourth quarter driven by sales of Primatene Mist, epinephrine products and glucagon. The company also revealed that it is anticipating a Q3 FY22 launch of vasopressin.
Amphastar Grows With Primatene Mist, Epinephrine And Glucagon
Amphastar has reported double-digit growth in the fourth quarter of 2021, as the company sees sales growth from Primatene Mist, epinephrine products and glucagon. The company also revealed that it is anticipating a Q3 FY22 launch of vasopressin.